JP Morgan maintains Definium Therapeutics at Overweight, raises price target to $85 from $84
JP Morgan kept its Overweight rating on Definium Therapeutics and increased its price target to $85 from $84, suggesting a 181.8% upside from the Nov 16 close of $30.16.


